IR
UTHR icon

Invictus RG’s United Therapeutics UTHR Stock Holding History

Invictus RG’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-417
Closed -$49K – 508
2017
Q3 		$49K Sell
417
-986
-70% -$126K 0.04% 372
2017
Q2 		$182K Buy
1,403
+1,313
+1,459% +$164K 0.13% 288
2017
Q1 		$12K Buy
+90
New +$13.6K 0.01% 675

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invictus RG's UTHR Position: Q4 2017 in Review

Invictus RG sold out of United Therapeutics (UTHR) in Q4 2017, closing a stake of 417 shares — an estimated $49K sold.

Invictus RG first reported a position in UTHR in Q1 2017 and held it in 3 quarters. The position peaked at $182K in Q2 2017. 400 funds tracked by Wall St. Rank hold UTHR as of Q4 2017.

  • Invictus RG reported no remaining United Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Invictus RG sold 417 United Therapeutics shares in Q4 2017, an estimated $49K.
  • Invictus RG first reported a position in United Therapeutics in Q1 2017 and held it in 3 quarters.
  • Invictus RG's United Therapeutics position peaked at $182K in Q2 2017.
  • 400 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2017.

Based on Invictus RG's 13F filing for Q4 2017, filed 13 Feb 2018.